DetailsCategory: DNA RNA and CellsPublished on Saturday, 27 August 2022 11:16Hits: 666
Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA
First cell product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasiontechnology, IL-15 cytokine support and a safety switch
Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory CD19 positive B-cell malignancies anticipated to begin in 2H22
PHILADELPHIA, PA, USA I August 25, 2022 I Century Therapeutics, Inc., (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, announced today that the company has been notified by the U.S. Food and Drug Administration (FDA) that the Companys ELiPSE-1 clinical study may proceed to assess CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies. CNTY-101 is the first allogeneic cell therapy product candidate engineered with four powerful and complementary functionalities, including a CD19 CAR for tumor targeting, IL-15 support for enhanced persistence, Allo-Evasiontechnology to prevent host rejection and enhance persistence and a safety switch to provide the option to eliminate the drug product if ever necessary. CNTY-101 is manufactured from a clonal iPSC master cell bank that yields homogeneous product, in which all infused cells have the intended modifications.
This IND clearance is a significant milestone for Century as we execute on our vision to merge two disruptive platforms, precision gene editing and the powerful potential of iPSCs, to potentially move the allogeneic cell therapy field forward, and continue on our path to becoming a leader in the space, said Lalo Flores, Chief Executive Officer, Century Therapeutics. We believe that CNTY-101, our first and wholly owned product candidate, will be the most technically advanced and differentiated CD19-targeted cell product when it enters the clinic, which is anticipated to occur later this year. We look forward to assessing the potential of Allo-Evasionto prevent immunological rejection and enhance persistence of multiple dosing of CNTY-101 regimens with the aim to increase the proportion of patients that achieve durable responses.
CNTY-101 is the first allogeneic cell product candidate with six genetic modifications incorporated using sequential rounds of CRISPR-mediated homologous recombination and repair that has received IND clearance by the FDA, said Luis Borges, Chief Scientific Officer, Century Therapeutics. We believe CNTY-101 will demonstrate the power of Centurys iPSC technology and cell engineering technology platforms. This accomplishment is a testament to the expertise and dedication of our team as we continue to make progress developing our pipeline of iPSC-derived NK and T cell product candidates.
The Phase 1 trial, ELiPSE-1 (NCT05336409), is intended to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CNTY-101 in patients with relapsed or refractory CD19-positive B-cell malignancies. All patients will receive an initial standard dose of conditioning chemotherapy consisting of cyclophosphamide (300 mg/m2) and fludarabine (30mg/m2) for 3 days. Schedule A of the trial includes a single-dose escalation of CNTY-101 and subcutaneous IL-2. Schedule B will evaluate a three-dose schedule per cycle of CNTY-101. Patients who demonstrate a clinical benefit are eligible for additional cycles of treatment with or without additional lymphodepletion pending FDA consent. We anticipate initiation of the Phase 1 trial later this year.
About Allo-Evasion
Centurys proprietary Allo-Evasiontechnology is used to engineer cell therapy product candidates with the potential to evade identification by the host immune system so they can be dosed multiple times without rejection, enabling increased persistence of the cells during the treatment period and potentially leading to deeper and more durable responses. More specifically, Allo-Evasion1.0 technology incorporates three gene edits designed to avoid recognition by patient/host CD8+ T cells, CD4+ T cells and NK cells. Knockout of beta-2-microglobulin or 2m, designed to prevent CD8+ T cell recognition, knock-out of the Class II Major Histocompatibility Complex Transactivator, or CIITA, designed to prevent CD4+ T cell recognition, and knock-in of the HLA-E gene, designed to enable higher expression of the HLA-E protein to prevent killing of CNTY-101 cells by host NK cells. Allo-Evasiontechnology may allow the implementation of more flexible and effective repeat dosing protocols for off-the-shelf product candidates.
About CNTY-101
CNTY-101 is an investigational off-the-shelf cancer immunotherapy product candidate that utilizes iPSC-derived natural killer (NK) cells with a CD19-directed chimeric antigen receptor (CAR) and includes Centurys core Allo-Evasionedits designed to overcome the three major pathways of host versus graft rejection - CD8+ T cells, CD4+ T cells and NK cells. In addition, the product candidate is engineered to express IL-15 to provide homeostatic cytokine support, which has been shown pre-clinically to improve functionality and persistence. Further, to potentially improve safety, the iNK cells were engineered with an EGFR safety switch, and proof-of-concept studies have demonstrated that the cells can be quickly eliminated by the administration of cetuximab, an antibody against EGFR approved by the U.S. Food and Drug Administration (FDA) for certain cancers. Initiation of the Phase 1, ELiPSE-1 trial in relapsed or refractory CD19-positive B-cell malignancies in multiple centers in the United States is anticipated to begin in the second half of 2022.
About Century Therapeutics
Century Therapeutics, Inc. (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visithttps://www.centurytx.com/.
SOURCE: Century Therapeutics
Read the original:
Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to...
- Principles of Genetic Engineering - PMC - National Center for ... - March 28th, 2024
- Historic Overview of Genetic Engineering Technologies for Human Gene ... - March 28th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - December 10th, 2023
- Genetically modified organism - Wikipedia - November 16th, 2023
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - November 16th, 2023
- 18 Human Genetic Engineering - Clemson University - April 7th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - April 7th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 12th, 2023
- Genetic Engineering Principles of Biology - December 27th, 2022
- Engineering the Perfect Baby | MIT Technology Review - December 27th, 2022
- What is CRISPR? | Live Science - November 24th, 2022
- To modify or not to modify? Genetic Modification and Gene Editing - A divergence by the UK - Lexology - October 13th, 2022
- DNA and the impossibility of research in isolation - Morning Star Online - October 13th, 2022
- Genome editing technologies: final conclusions of the re-examination of Article 13 of the Oviedo Convention - Council of Europe - October 13th, 2022
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 13th, 2022
- Dissatisfaction and New Articulations - Discovery Institute - October 13th, 2022
- In 'The Cultivar Series,' Uli Westphal Gets to the Root of Crop Diversity and Agricultural Modification - Colossal - October 13th, 2022
- Genomic Research Aids in the Effort to Understand How Best to Treat Deadly Infections Caused by a Fungus - UMass News and Media Relations - October 13th, 2022
- Synthetic Biology Market is Expected to Report a CAGR of ~21% from 2021 to 2029: Industry Size, Growth & Forecast at Douglas Insights - Yahoo... - October 13th, 2022
- Farmers, consumers will embrace GMOs if they understand them - The Standard - October 13th, 2022
- Emily Whitten: The limits of science and human intelligence - WORLD News Group - October 13th, 2022
- Behind this Nobel prize is a very human story: theres a bit of Neanderthal in all of us - The Guardian - October 13th, 2022
- Earth materials in technology The National - The National - October 13th, 2022
- Gene therapy brings hope to people with sickle cell, HIV - Monitor - October 13th, 2022
- Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic... - October 13th, 2022
- Skin Grafting, Cryopreservation, and Diseases: A Review Article - Cureus - October 13th, 2022
- Cultured meat could help solve the climate crisis. Heres what it will take to move it from the lab to the dinner table - Fortune - October 13th, 2022
- Ignore scary messages: We've never had it so good & that's not manure - West Side Index & Gustine Press-Standard - October 13th, 2022
- Global Phosphoramidite Market Report 2022: Increasing Synthetic Nucleotide Applications in Therapeutics Drives Growth - ResearchAndMarkets.com -... - October 13th, 2022
- Enzymes Market worth $16.9 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance - October 4th, 2022
- Experts Sound Alarm Over 'Growing Threat' of Genetically Engineered Trees - Common Dreams - October 4th, 2022
- Scientists are manipulating the DNA of mosquitoes to fight the spread of malaria - Euronews - October 4th, 2022
- Smile Coffee Werks upgraded its coffee beans to Fair Trade and USDA Organic - Vending Market Watch - October 4th, 2022
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 4th, 2022
- 22nd Century Group (Nasdaq: XXII) Expands VLN Distributor Network with the Addition of Specialty Distrib - Benzinga - October 4th, 2022
- Researchers are seeking to develop spuds that resist harmful nematodes - FreshPlaza.com - October 4th, 2022
- Synthetic biology has the power to cure and kill. How will we use it? - Big Think - September 25th, 2022
- SPECIAL REPORT: Bioengineered food labeling: 'They kind of shot in the middle and missed every constituency' - FoodNavigator-USA.com - September 25th, 2022
- Yeast-Fermented Chemo: Now We Can Brew Anything - Medscape - September 25th, 2022
- September 23, 2022: The Integrity of Marius Mason WFHB - WFHB News - September 25th, 2022
- 2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years - The Motley Fool - September 25th, 2022
- Bananas threatened by devastating fungus given temporary resistance - New Scientist - September 25th, 2022
- 'What Hath God Wrought' - Today, Luddites Are Concerned About Weedkillers Like They Once Were The Telegraph - Science 2.0 - September 25th, 2022
- Children should be educated about oral health and hygiene - Star of Mysore - September 25th, 2022
- Id rather eat an actual burger: why plant-based meats sizzle fizzled in the US - The Guardian - September 25th, 2022
- Health Tech startups are booming. These 11 VC investors are behind some of the hottest deals - Fortune - September 25th, 2022
- Last Chance This Fall to Tell the NOSB To Uphold Organic Integrity - Beyond Pesticides - September 25th, 2022
- Cambodian PM begins official visit to Cuba - Khmer Times - September 25th, 2022
- Researchers develop method to prevent spread of melanoma to brain - Xinhua - September 25th, 2022
- I'm allergic to the cat, what can I do? - Surinenglish.com - September 25th, 2022
- Researchers Propose a New Way of Regulating Engineered Crops - Modern Farmer - September 16th, 2022
- Purple Tomato is first genetically engineered plant to be deregulated through USDA's new regulatory status review process - Lexology - September 16th, 2022
- Genetically Modified Feed Market to Hit $135 billion by 2030, says Global Market Insights Inc. - Yahoo Finance - September 16th, 2022
- Africa, GMOs and Western Interests - DW (English) - September 16th, 2022
- The science behind the oil supply breakdown in 'Last Light' - Syfy - September 16th, 2022
- Inside the controversial plan to bring extinct animals back from the dead - The Independent - September 16th, 2022
- Star Trek Actor Says Their Trek Hero Is Just Like Their Marvel Character - Giant Freakin Robot - September 16th, 2022
- Scientists closer to making blood stem cells in the lab - Cosmos - September 16th, 2022
- Oncolytic Cancer Therapies Market is expected to grow at a CAGR of 33% by 2032 | DelveInsight - Digital Journal - September 16th, 2022
- Don't call it waste - it can be turned into hydrogen if you handle it right - Innovation Origins - September 16th, 2022
- Can gene editing ease the cost of living crisis? - The Grocer - September 8th, 2022
- Gene editing could revive the American chestnut tree and help fight climate change but familiar anti-biotechonology activist critics will have none... - September 8th, 2022
- Colossal to de-extinct the Tasmanian tiger. Is it a safe thing to do? - Cape Cod Times - September 8th, 2022
- The Future of Nanotech, the World's Tiniest Industry - Entrepreneur - September 8th, 2022
- Viewpoint: The 'natural food' sham 'Effective communication on the ethics of science may be hindered by appeals to naturalness' - Genetic Literacy... - September 8th, 2022
- Toray says it has developed the worlds first 100% bio-based adipic acid - Biofuels Digest - September 8th, 2022
- Chinese scientists claim to have engineered the world's first mouse with fully reprogrammed genes - Interesting Engineering - August 30th, 2022
- Living Carbon: The startup setting down roots from 9 to 5 | Greenbiz - GreenBiz - August 30th, 2022
- Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through... - August 30th, 2022
- Genetics in fiction - Wikipedia - August 14th, 2022
- Weeds superpower could help feed the planet - Freethink - August 14th, 2022
- POSEIDA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - August 14th, 2022
- Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma - Genetic Engineering & Biotechnology News - August 14th, 2022
- LETTER TO THE EDITOR: Lessons from 1984 | Letters To Editor | carolinacoastonline.com - Carolinacoastonline - August 14th, 2022
- How Arkeon Biotechnologies is turning CO2 into food: 'Excuse my language, but this is next-level cool' - FoodNavigator.com - August 14th, 2022
- Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks - PR Newswire - August 14th, 2022
- THE SAD STORY OF THE REJECTION OF SCIENCE - Sp Supplements - DAWN.COM - DAWN.com - August 14th, 2022
- Global Genome Editing Technologies market is projected to grow at a CAGR of 15.96% by 2032: Visiongain Reports Ltd - Yahoo Finance - August 5th, 2022
- I Got Critiqued by YouTuber Gutsick Gibbon - Discovery Institute - August 5th, 2022
- CRISPR Technology in the Agricultural Industry: Patent and Regulatory Updates - JD Supra - August 5th, 2022